Log In
BCIQ
Print this Print this
 

AMP-110

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFusion protein containing the extracellular domain of B7-H4 (V-set domain containing T cell activation inhibitor; VTCN1) and the Fc-portion of IgG
Molecular Target V-set domain containing T cell activation inhibitor 1 (B7-H4) (VTCN1)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/14/2013

Undisclosed

0

Undisclosed

Get a free BioCentury trial today